- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...

BRIDGEWATER, N.J., January 23, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has ...

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic ...

Actavis and Adamas Pharmaceuticals Inc announced that the US Food and Drug Administration (US FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine ...

July 21, 2004 (Philadelphia) — Results of a phase III trial of memantine hydrochloride monotherapy in patients with mild to moderate Alzheimer's disease suggest that the drug is effective at all ...

You have full access to this article via your institution. In June 2000, Merz and Forest announced a development and marketing agreement for memantine in the United States for the treatment of AD and ...

Please provide your email address to receive an email when new articles are posted on . Cognitive decline is one of the potential adverse effects of cranial radiation therapy in cancer patients. It ...

The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...

Forest Laboratories announced that it has submitted a New Drug Application (NDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER), a receptor antagonist and donepezil HCl, ...

Please provide your email address to receive an email when new articles are posted on . Response rates on the SRS-2 and CGI-S were significantly higher in those given memantine. Memantine was also ...